Dynamics of Drug Resistance: Optimal Control of an Infectious Disease.

Operations Research
Naveed ChehraziEva A Enns

Abstract

Antimicrobial resistance is a significant public health threat. In the U.S. alone, 2 million people are infected and 23,000 die each year from antibiotic resistant bacterial infections. In many cases, infections are resistant to all but a few remaining drugs. We examine the case where a single drug remains and solve for the optimal treatment policy for an SIS infectious disease model incorporating the effects of drug resistance. The problem is formulated as an optimal control problem with two continuous state variables, the disease prevalence and drug's "quality" (the fraction of infections that are drug-susceptible). The decision maker's objective is to minimize the discounted cost of the disease to society over an infinite horizon. We provide a new generalizable solution approach that allows us to thoroughly characterize the optimal treatment policy analytically. We prove that the optimal treatment policy is a bang-bang policy with a single switching time. The action/inaction regions can be described by a single boundary that is strictly increasing when viewed as a function of drug quality, indicating that when the disease transmission rate is constant, the policy of withholding treatment to preserve the drug for a potentiall...Continue Reading

References

Feb 1, 1980·Disease-a-month : DM·P J Wiesner, S E Thompson
Oct 1, 1996·The Journal of Infectious Diseases·G P Garnett, R M Anderson
Oct 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·S BonhoefferB R Levin
Mar 21, 1998·Science·R J Williams, D L Heymann
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·J BjörkmanD I Andersson
Apr 16, 1998·The Journal of Infectious Diseases·N I StilianakisF G Hayden
Oct 6, 1999·Current Opinion in Microbiology·D I Andersson, B R Levin
Dec 1, 2000·Sexually Transmitted Diseases·G P Garnett, F J Bowden
Mar 22, 2003·Preventive Medicine·Thomas A FarleyWhitney Elkins
May 27, 2003·Science·Marc LipsitchMegan Murray
Nov 22, 2005·BMJ : British Medical Journal·Patricia CaneUNKNOWN UK Group on Transmitted HIV Drug Resistance
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E Cosgrove
Feb 24, 2006·The New England Journal of Medicine·Frederick G Hayden
Dec 14, 2006·The Journal of Infectious Diseases·Frederick G Hayden, Andrew T Pavia
Jan 27, 2007·PLoS Medicine·Marc LipsitchBruce R Levin
May 18, 2007·Proceedings. Biological Sciences·Murray E AlexanderPing Yan
Jul 4, 2007·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Ameeta Eshri SinghTom Wong
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brad SpellbergUNKNOWN Infectious Diseases Society of America
Mar 20, 2008·PloS One·Seyed M MoghadasJianhong Wu
Nov 1, 2008·Virology Journal·Stefan O BrockmannMartin Eichner
Jan 22, 2009·BMC Infectious Diseases·Martin EichnerBeatriz Vidondo
Jan 31, 2009·The New England Journal of Medicine·Cesar A Arias, Barbara E Murray
Mar 4, 2009·JAMA : the Journal of the American Medical Association·Nila J DharanUNKNOWN Oseltamivir-Resistance Working Group
Mar 5, 2009·The New England Journal of Medicine·Anne Moscona
Jan 1, 2008·Operations Research·Elisa F LongMargaret L Brandeau
Mar 3, 2011·Mathematical Biosciences and Engineering : MBE·Paula A González-ParraCarlos Castillo-Chavez
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Dec 14, 2011·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Joanna JefferisPeter Rose
Feb 10, 2012·The New England Journal of Medicine·Gail A BolanJudith N Wasserheit
Jun 16, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew J NeidellElaine L Larson
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Oct 4, 2012·Expert Review of Anti-infective Therapy·Sarah KiddGail Bolan
Dec 13, 2012·Future Microbiology·Magnus Unemo, Robert A Nicholas
Jan 25, 2013·The New England Journal of Medicine·Brad SpellbergDavid N Gilbert
Feb 14, 2013·Sexually Transmitted Diseases·Catherine Lindsey SatterwhiteHillard Weinstock
Feb 14, 2013·Sexually Transmitted Diseases·Kwame Owusu-EduseiCharlotte K Kent
Mar 9, 2013·The Journal of Infectious Diseases·William M GeislerEdward W Hook
Apr 5, 2013·Clinical Microbiology Reviews·Alejandro BeceiroGermán Bou
May 11, 2013·American Journal of Epidemiology·Ian H SpicknallJoseph N S Eisenberg
Nov 21, 2013·The Lancet Infectious Diseases·Ramanan LaxminarayanOtto Cars
Apr 2, 2014·Current Opinion in Infectious Diseases·Lindley A Barbee
Jul 2, 2014·Clinical Microbiology Reviews·Magnus Unemo, William M Shafer
Mar 7, 2015·Mayo Clinic Proceedings·Shawn VasooPritish K Tosh
May 1, 2015·Journal of Mathematical Biology·Yanyu XiaoSeyed M Moghadas

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.